{"id":"https://openalex.org/W2586893870","doi":"https://doi.org/10.1097/fpc.0000000000000268","title":"Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes","display_name":"Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes","alternate_titles":[],"publication_year":2017,"publication_date":"2017-02-09","ids":{"openalex":"https://openalex.org/W2586893870","doi":"https://doi.org/10.1097/fpc.0000000000000268","mag":"2586893870","pmid":"https://pubmed.ncbi.nlm.nih.gov/28134748"},"language":"en","primary_location":{"id":"doi:10.1097/fpc.0000000000000268","doi":"https://doi.org/10.1097/fpc.0000000000000268","is_oa":false,"landing_page_url":"https://doi.org/10.1097/fpc.0000000000000268","pdf_url":null,"source":{"id":"https://openalex.org/S192301155","display_name":"Pharmacogenetics and Genomics","issn_l":"1744-6872","issn":["1744-6872","1744-6880"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacogenetics and Genomics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2586893870"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=50996","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028918694","display_name":"Heike Zimdahl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]},{"id":"https://openalex.org/I4210160326","display_name":"German Center for Diabetes Research","ror":"https://ror.org/04qq88z54","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4210160326","https://openalex.org/I4405256427"]},{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Heike Zimdahl","raw_affiliation_strings":["aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach bGerman Center for Diabetes Research (DZD) cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg hBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany iEli Lilly and Company, Indianapolis, USA","* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach bGerman Center for Diabetes Research (DZD) cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg hBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672","https://openalex.org/I4210160326","https://openalex.org/I8087733"]},{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040811419","display_name":"Axel Haupt","orcid":"https://orcid.org/0000-0003-4502-0470","observed_orcids":["https://orcid.org/0000-0003-4502-0470"]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Axel Haupt","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michael Brendel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Brendel","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113981050","display_name":"Louis Bour","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Louis Bour","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110063923","display_name":"Fausto E Machicao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Fausto Machicao","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073988431","display_name":"Afshin Salsali","orcid":"https://orcid.org/0000-0003-2763-0486","observed_orcids":["https://orcid.org/0000-0003-2763-0486"]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Afshin Salsali","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012223927","display_name":"Uli C. Broedl","orcid":"https://orcid.org/0000-0001-9893-7747","observed_orcids":["https://orcid.org/0000-0001-9893-7747"]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uli C. Broedl","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113554665","display_name":"Hans\u2010Juergen Woerle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hans-Juergen Woerle","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084404405","display_name":"Hans\u2010Ulrich H\u00e4ring","orcid":"https://orcid.org/0000-0003-4655-9937","observed_orcids":["https://orcid.org/0000-0003-4655-9937"]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Hans-Ulrich H\u00e4ring","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081400849","display_name":"Harald Staiger","orcid":"https://orcid.org/0000-0002-9507-5333","observed_orcids":["https://orcid.org/0000-0002-9507-5333"]},"institutions":[{"id":"https://openalex.org/I3018134672","display_name":"Helmholtz Munich","ror":"https://ror.org/00cfam450","country_code":"DE","type":"facility","lineage":["https://openalex.org/I1305996414","https://openalex.org/I3018134672"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Harald Staiger","raw_affiliation_strings":["* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"* Heike Zimdahl and Axel Haupt contributed equally to the writing of this article.; Accepted January 6, 2017; Received April 13, 2016; aBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach; cInstitute for Diabetes Research and Metabolic Diseases, Helmholtz Centre Munich; dDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology, and Clinical Chemistry; e-mail: [email\u00a0protected]; eInterfaculty Centre for Pharmacogenomics and Pharma Research, University of Tuebingen; fInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University Tuebingen, Tuebingen; fax: +49 735 1 83 94835; gInstitute of Experimental Genetics, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg; iEli Lilly and Company, Indianapolis, USA","institution_ids":["https://openalex.org/I3018134672"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5028918694"],"corresponding_institution_ids":["https://openalex.org/I3018134672","https://openalex.org/I4210160326","https://openalex.org/I8087733"],"apc_list":null,"apc_paid":null,"fwci":2.4973,"has_fulltext":false,"cited_by_count":55,"citation_normalized_percentile":{"value":0.87161093,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"27","issue":"4","first_page":"135","last_page":"142"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.42899999022483826,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.42899999022483826,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10261","display_name":"Genetic Associations and Epidemiology","score":0.2502000033855438,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.24400000274181366,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/slc5a2","display_name":"SLC5A2","score":0.9629999995231628},{"id":"https://openalex.org/keywords/sglt2","display_name":"SGLT2","score":0.824999988079071},{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.9750000238418579},{"id":"https://openalex.org/keywords/single-nucleotide-polymorphisms","display_name":"single nucleotide polymorphisms","score":0.8960000276565552},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.8880000114440918},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.984000027179718},{"id":"https://openalex.org/keywords/diabetes-risk","display_name":"diabetes risk","score":0.7210000157356262},{"id":"https://openalex.org/keywords/metabolic-phenotypes","display_name":"metabolic phenotypes","score":0.7649999856948853},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.7089999914169312},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9070000052452087},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.765999972820282},{"id":"https://openalex.org/keywords/genetic-variants","display_name":"genetic variants","score":0.4490000009536743}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9583103060722351},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7370940446853638},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6545351147651672},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6536675095558167},{"id":"https://openalex.org/C55775858","wikidata":"https://www.wikidata.org/wiki/Q1152227","display_name":"Pharmacogenetics","level":4,"score":0.6520347595214844},{"id":"https://openalex.org/C153209595","wikidata":"https://www.wikidata.org/wiki/Q501128","display_name":"Single-nucleotide polymorphism","level":4,"score":0.6272368431091309},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5899595618247986},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.548405647277832},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.43616044521331787},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.43035730719566345},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.33323872089385986},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23551973700523376},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.2287897765636444},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.19704851508140564},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.129771888256073},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D001794","descriptor_name":"Blood Pressure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003430","descriptor_name":"Cross-Sectional Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020022","descriptor_name":"Genetic Predisposition to Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020641","descriptor_name":"Polymorphism, Single Nucleotide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051297","descriptor_name":"Sodium-Glucose Transporter 2","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1097/fpc.0000000000000268","doi":"https://doi.org/10.1097/fpc.0000000000000268","is_oa":false,"landing_page_url":"https://doi.org/10.1097/fpc.0000000000000268","pdf_url":null,"source":{"id":"https://openalex.org/S192301155","display_name":"Pharmacogenetics and Genomics","issn_l":"1744-6872","issn":["1744-6872","1744-6880"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacogenetics and Genomics","raw_type":"journal-article"},{"id":"pmid:28134748","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28134748","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacogenetics and genomics","raw_type":"Journal Article"},{"id":"pmh:oai:opus-zb.helmholtz-muenchen.de:50996","doi":null,"is_oa":true,"landing_page_url":"https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=50996","pdf_url":null,"source":{"id":"https://openalex.org/S4377196115","display_name":"Site cant be reached","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacogenet. Genomics 27, 135-142 (2017)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:opus-zb.helmholtz-muenchen.de:50996","doi":null,"is_oa":true,"landing_page_url":"https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=50996","pdf_url":null,"source":{"id":"https://openalex.org/S4377196115","display_name":"Site cant be reached","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacogenet. Genomics 27, 135-142 (2017)","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1976793989","https://openalex.org/W1993282909","https://openalex.org/W1996042816","https://openalex.org/W2049240940","https://openalex.org/W2051243940","https://openalex.org/W2055864845","https://openalex.org/W2089514748","https://openalex.org/W2090207011","https://openalex.org/W2098225835","https://openalex.org/W2099484221","https://openalex.org/W2101374656","https://openalex.org/W2103196856","https://openalex.org/W2114756460","https://openalex.org/W2128219379","https://openalex.org/W2133469996","https://openalex.org/W2133795831","https://openalex.org/W2137069992","https://openalex.org/W2138270253","https://openalex.org/W2144213974","https://openalex.org/W2155104557","https://openalex.org/W2160234571","https://openalex.org/W2160471487","https://openalex.org/W2163029902","https://openalex.org/W2164368208","https://openalex.org/W2171471305","https://openalex.org/W4211183127"],"related_works":["https://openalex.org/W7119925815","https://openalex.org/W4387527826","https://openalex.org/W3189768925","https://openalex.org/W4412098987","https://openalex.org/W4387539559","https://openalex.org/W2975306105","https://openalex.org/W6921383247","https://openalex.org/W4403452836","https://openalex.org/W2610402627","https://openalex.org/W4401195803"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Inhibition":[1],"of":[2,16,100,132],"the":[3,14,32,58,122,128,133,186,190,198,217],"renal":[4],"sodium-glucose":[5],"cotransporter":[6],"2":[7,46,67,87],"(SGLT2)":[8],"is":[9],"a":[10,74,208],"novel":[11],"concept":[12],"in":[13,31,40,63,121,189,197],"therapy":[15],"diabetes":[17,47,88],"mellitus.":[18],"In":[19,127],"this":[20],"study,":[21,130],"we":[22],"first":[23],"assessed":[24],"whether":[25,50],"common":[26,114],"single":[27],"nucleotide":[28],"polymorphisms":[29],"(SNPs)":[30],"SGLT2-encoding":[33],"gene":[34,124,200],"SLC5A2":[35,123,134,199],"affect":[36],"diabetes-related":[37,203],"metabolic":[38,138,204],"traits":[39,139,205],"subjects":[41],"at":[42,82],"risk":[43,84],"for":[44,85,112,185],"type":[45,66,86],"and,":[48],"second,":[49],"these":[51],"have":[52,207],"pharmacogenetic":[53,91,191],"relevance":[54],"by":[55],"interfering":[56],"with":[57,65,172,216],"response":[59,169,213],"to":[60,170,214],"empagliflozin":[61,101,173],"treatment":[62,171,215],"patients":[64,94],"diabetes.":[68],"PATIENTS":[69],"AND":[70],"METHODS:":[71],"Samples":[72],"from":[73,93,95],"metabolically":[75],"well-phenotyped":[76],"cross-sectional":[77,129],"study":[78],"population":[79],"(total":[80],"N=2600)":[81],"increased":[83],"and":[89],"pooled":[90],"samples":[92],"four":[96],"phase":[97],"III":[98],"trials":[99],"(in":[102],"total:":[103],"603":[104],"receiving":[105,108],"empagliflozin,":[106],"305":[107],"placebo)":[109],"were":[110],"genotyped":[111],"five":[113],"SNPs":[115,135,187],"(minor":[116],"allele":[117],"frequencies":[118],"\u22655%)":[119],"present":[120],"locus.":[125],"RESULTS:":[126],"none":[131],"significantly":[136],"influenced":[137],"such":[140],"as":[141],"body":[142],"fat,":[143],"insulin":[144,146],"sensitivity/resistance,":[145],"release,":[147],"HbA1c,":[148,175],"plasma":[149],"glucose,":[150,177],"or":[151,179],"systolic":[152,180],"blood":[153,181],"pressure":[154,182],"when":[155],"multiple":[156],"testing":[157],"was":[158,183],"taken":[159],"into":[160],"account":[161],"(all":[162],"P\u22650.0083).":[163],"Further,":[164],"no":[165],"relevant":[166,210],"effect":[167],"on":[168,174,212],"fasting":[176],"weight,":[178],"observed":[184],"tested":[188],"study.":[192],"CONCLUSION:":[193],"Common":[194],"genetic":[195],"variants":[196],"neither":[201],"affects":[202],"nor":[206],"clinically":[209],"impact":[211],"SGLT2":[218],"inhibitor":[219],"empagliflozin.":[220]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2586893870","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-02-17T00:00:00"}
